长链非编码 RNA 在多发性硬化症发病机制中的最新研究进展。
Recent advances of long noncoding RNAs involved in the development of multiple sclerosis.
机构信息
School of Life Science and Technology, China Pharmaceutical University, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Nanjing 210009, China.
Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
出版信息
Chin J Nat Med. 2020 Jan;18(1):36-46. doi: 10.1016/S1875-5364(20)30003-0.
Given the rapid increase of patients with autoimmune diseases and the lack of satisfactory therapies, the discovery of novel and effective therapeutic targets have been in an urgent demand. Recent studies have revealed that long noncoding RNAs (lncRNAs) play crucial roles in the development of multiple sclerosis (MS), which provides a new opportunity of uncovering novel mechanism associated with the progression of MS. This review highlights the dysregulation of lncRNAs in the development of MS in patients and animal models. Additionally, the potential clinical relevance of lncRNAs severed as therapeutic targets and diagnostic markers are discussed.
鉴于自身免疫性疾病患者的迅速增加以及缺乏令人满意的治疗方法，因此迫切需要发现新的有效治疗靶点。最近的研究表明，长链非编码 RNA（lncRNA）在多发性硬化症（MS）的发展中起着至关重要的作用，这为揭示与 MS 进展相关的新机制提供了新的机会。本综述强调了 lncRNA 在患者和动物模型中 MS 发展中的失调。此外，还讨论了作为治疗靶点和诊断标志物的 lncRNA 的潜在临床相关性。
Zotero 插件